⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TRVI News
Trevi Therapeutics, Inc. Common Stock
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
globenewswire.com
TRVI
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
globenewswire.com
TRVI
Trevi Therapeutics to Participate in Upcoming Events
globenewswire.com
TRVI
Form 8-K
sec.gov
TRVI
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
globenewswire.com
TRVI
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026
globenewswire.com
TRVI
Form 8-K
sec.gov
TRVI
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
globenewswire.com
TRVI
Trevi Therapeutics to Participate in Upcoming March Conferences
globenewswire.com
TRVI
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
globenewswire.com
TRVI